Unum Therapeutics Funding & Investors
Cambridge, MA
Cogent Biosciences, Inc. operates as a biotechnology company. The Company focuses on development and commercialization of solutions to treat cancers, autoimmune conditions, and rare diseases. Cogent Biosciences serves patients worldwide.
unumrx.comTotal Amount Raised: $917,700,032
Unum Therapeutics Funding Rounds
Post Ipo Equity
$225,000,000
Post Ipo Equity Investors
Commodore CapitalDeerfield ManagementTCG Crossover ManagementRedmile GroupVenrock Healthcare Capital PartnersJanus HealthAdage Capital ManagementPerceptive AdvisorsFairmount Funds ManagementPost Ipo Equity
$150,000,000
Post Ipo Equity
$150,000,000
Post Ipo Equity
$60,000,000
Post Ipo Equity
$104,400,000
Post Ipo Equity Investors
Fairmount Funds ManagementAcorn BioventuresBiotechnology Value FundABGOrbiMed AdvisorsAtlas VentureSamsara BioCapitalRTW InvestmentsPerceptive AdvisorsVenrock Healthcare Capital PartnersCommodore CapitalLogos Global ManagementPost Ipo Equity
$50,000,000
Corporate Round
$86,000,000
IPO
Unknown
Debt Financing
$15,000,000
Debt Financing Investors
Square 1 BankSeries B
$65,000,000
Series B Investors
New Leaf Venture PartnersJennison AssociatesNovo HoldingsSabby ManagementSectoral Asset ManagementAtlas VentureWellington ManagementSanofi VenturesSeagenF-Prime CapitalCowen GroupBrace Pharma CapitalSeries A
$12,300,000
Series A Investors
Atlas VentureF-Prime CapitalSanofi VenturesEight Roads Ventures
Funding info provided by Diffbot.